share_log

Analyst Ratings For Genmab

Benzinga ·  Mar 26 22:00

Across the recent three months, 6 analysts have shared their insights on Genmab (NASDAQ:GMAB), expressing a variety of opinions spanning from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings51000
Last 30D10000
1M Ago10000
2M Ago31000
3M Ago00000

The 12-month price targets, analyzed by analysts, offer insights with an average target of $49.67, a high estimate of $50.00, and a low estimate of $48.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.16%.

price target chart

Exploring Analyst Ratings: An In-Depth Overview

The standing of Genmab among financial...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment